Randomized trial · people
Eloralintide: 2.6% to 11.3% weight loss at 12 weeks in phase 1
Checked against the paper Randomized trialPublished by PepVault
The takeaway
Early human data on eloralintide show weight loss within 12 weeks of weekly dosing, with gut side effects less common than appetite loss, headache and fatigue.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 100
- Published
- 2026
- Journal
- Diabetes Obes Metab
What they tested
The team tested whether once-weekly eloralintide shots, an amylin receptor agonist, were safe and well tolerated, how the drug behaved in the body, and what they did to body weight in people with obesity or overweight.
How the study was done
A randomized, placebo-controlled, phase 1 trial at US centers, in which 100 people with obesity or overweight (average age 44, 29% women, average BMI 32.6 kg/m2) got weekly shots under the skin of eloralintide or placebo (a dummy shot) for 12 weeks. Neither participants nor investigators knew who got which, and people were placed in 5 cohorts at rising doses, each starting on their full dose without stepping up.

Model. Individual results vary.
What they found
At week 12, people on eloralintide lost an average of 2.6% to 11.3% of body weight depending on dose group, measured as a least squares mean (a model-adjusted average). Appetite loss was the side effect seen most often, in 19% of people on the drug; others included COVID-19 (11%), fatigue (11%) and headache (12%), and most side effects were mild. Gut problems were less frequent, with vomiting in 4%, nausea in 8% and diarrhea in 10%. Nobody died, and the single serious adverse event, in the 6 mg cohort, was judged not caused by the drug.
What it doesn’t show
This was a small, 12-week early-stage trial built mainly to check safety and drug levels, so it can't show how weight loss holds up over longer use or in a broader group. Most participants were men, and all were treated at US centers.
The paper
Bhattachar et al. Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes Obes Metab. 2026.
The compound
More studies on Eloralintide
- Eloralintide: -4.4% body weight at week 4 in a single-dose trialRandomized trial · people · 2025
- Every study on Eloralintide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.